Published in JAMA on March 14, 2012
Molecular Characterization of Neuroblastic Tumor: Correlation With Clinical Outcome | NCT00588068
The genetic landscape of high-risk neuroblastoma. Nat Genet (2013) 4.71
Frequent ATRX, CIC, FUBP1 and IDH1 mutations refine the classification of malignant gliomas. Oncotarget (2012) 3.88
Integrated genomic analyses identify ARID1A and ARID1B alterations in the childhood cancer neuroblastoma. Nat Genet (2012) 3.38
Targeting MYCN in neuroblastoma by BET bromodomain inhibition. Cancer Discov (2013) 3.11
The Pediatric Cancer Genome Project. Nat Genet (2012) 2.49
Neuroblastoma: developmental biology, cancer genomics and immunotherapy. Nat Rev Cancer (2013) 2.44
Recurrent somatic structural variations contribute to tumorigenesis in pediatric osteosarcoma. Cell Rep (2014) 2.27
The landscape of somatic mutations in epigenetic regulators across 1,000 paediatric cancer genomes. Nat Commun (2014) 1.90
Relapsed neuroblastomas show frequent RAS-MAPK pathway mutations. Nat Genet (2015) 1.82
Neuroblastoma and MYCN. Cold Spring Harb Perspect Med (2013) 1.75
Every amino acid matters: essential contributions of histone variants to mammalian development and disease. Nat Rev Genet (2014) 1.62
Cancer genome-sequencing study design. Nat Rev Genet (2013) 1.55
Mutations in regulators of the epigenome and their connections to global chromatin patterns in cancer. Nat Rev Genet (2013) 1.53
Dual CDK4/CDK6 inhibition induces cell-cycle arrest and senescence in neuroblastoma. Clin Cancer Res (2013) 1.51
Mutational dynamics between primary and relapse neuroblastomas. Nat Genet (2015) 1.36
ALK mutations confer differential oncogenic activation and sensitivity to ALK inhibition therapy in neuroblastoma. Cancer Cell (2014) 1.36
Telomerase activation by genomic rearrangements in high-risk neuroblastoma. Nature (2015) 1.32
Neuroblastoma: molecular pathogenesis and therapy. Annu Rev Med (2014) 1.21
Advances in Risk Classification and Treatment Strategies for Neuroblastoma. J Clin Oncol (2015) 1.19
Mechanisms of neuroblastoma regression. Nat Rev Clin Oncol (2014) 1.17
Histone H3.3 mutations: a variant path to cancer. Cancer Cell (2013) 1.07
TERT rearrangements are frequent in neuroblastoma and identify aggressive tumors. Nat Genet (2015) 1.05
ATRX: the case of a peculiar chromatin remodeler. Epigenetics (2012) 1.03
Advances in the translational genomics of neuroblastoma: From improving risk stratification and revealing novel biology to identifying actionable genomic alterations. Cancer (2015) 1.01
Pediatric solid tumor genomics and developmental pliancy. Oncogene (2015) 1.00
Rare variants in TP53 and susceptibility to neuroblastoma. J Natl Cancer Inst (2014) 1.00
Atrx deficiency induces telomere dysfunction, endocrine defects, and reduced life span. J Clin Invest (2013) 0.98
CODEX: a normalization and copy number variation detection method for whole exome sequencing. Nucleic Acids Res (2015) 0.97
A LIN28B-RAN-AURKA Signaling Network Promotes Neuroblastoma Tumorigenesis. Cancer Cell (2015) 0.97
Platform comparison for evaluation of ALK protein immunohistochemical expression, genomic copy number and hotspot mutation status in neuroblastomas. PLoS One (2014) 0.96
Assessing telomeric DNA content in pediatric cancers using whole-genome sequencing data. Genome Biol (2012) 0.95
Atrx promotes heterochromatin formation at retrotransposons. EMBO Rep (2015) 0.94
PML bodies provide an important platform for the maintenance of telomeric chromatin integrity in embryonic stem cells. Nucleic Acids Res (2013) 0.92
Ultra-High Density SNParray in Neuroblastoma Molecular Diagnostics. Front Oncol (2014) 0.90
CASC15-S Is a Tumor Suppressor lncRNA at the 6p22 Neuroblastoma Susceptibility Locus. Cancer Res (2015) 0.89
Striking dichotomy in outcome of MYCN-amplified neuroblastoma in the contemporary era. Cancer (2014) 0.89
Systems genomics evaluation of the SH-SY5Y neuroblastoma cell line as a model for Parkinson's disease. BMC Genomics (2014) 0.88
ATRX represses alternative lengthening of telomeres. Oncotarget (2015) 0.88
Whole-exome sequencing identifies somatic ATRX mutations in pheochromocytomas and paragangliomas. Nat Commun (2015) 0.87
Therapeutic targets for neuroblastomas. Expert Opin Ther Targets (2014) 0.87
Structural variation discovery in the cancer genome using next generation sequencing: computational solutions and perspectives. Oncotarget (2015) 0.85
Epigenetic siRNA and Chemical Screens Identify SETD8 Inhibition as a Therapeutic Strategy for p53 Activation in High-Risk Neuroblastoma. Cancer Cell (2017) 0.84
Absolute leukocyte telomere length in HIV-infected and uninfected individuals: evidence of accelerated cell senescence in HIV-associated chronic obstructive pulmonary disease. PLoS One (2015) 0.83
Decreased expression of the chromatin remodeler ATRX associates with melanoma progression. J Invest Dermatol (2014) 0.82
The Childhood Solid Tumor Network: A new resource for the developmental biology and oncology research communities. Dev Biol (2015) 0.82
Histone variant H3.3 provides the heterochromatic H3 lysine 9 tri-methylation mark at telomeres. Nucleic Acids Res (2015) 0.82
De novo engineering of a human cystathionine-γ-lyase for systemic (L)-Methionine depletion cancer therapy. ACS Chem Biol (2012) 0.82
Intratumoral diversity of telomere length in individual neuroblastoma tumors. Oncotarget (2015) 0.82
Quantitative phosphoproteomic analysis identifies activation of the RET and IGF-1R/IR signaling pathways in neuroblastoma. PLoS One (2013) 0.81
Massively parallel sequencing reveals an accumulation of de novo mutations and an activating mutation of LPAR1 in a patient with metastatic neuroblastoma. PLoS One (2013) 0.81
Absence of telomerase reverse transcriptase promoter mutations in neuroblastoma. Biomed Rep (2015) 0.80
Development and characterization of a human orthotopic neuroblastoma xenograft. Dev Biol (2015) 0.80
Common genetic variants associated with telomere length confer risk for neuroblastoma and other childhood cancers. Carcinogenesis (2016) 0.80
Implementation of next generation sequencing into pediatric hematology-oncology practice: moving beyond actionable alterations. Genome Med (2016) 0.79
Preclinical Models Provide Scientific Justification and Translational Relevance for Moving Novel Therapeutics into Clinical Trials for Pediatric Cancer. Cancer Res (2015) 0.79
Neuroblastoma: oncogenic mechanisms and therapeutic exploitation of necroptosis. Cell Death Dis (2015) 0.79
Genomic sequencing in cancer. Cancer Lett (2012) 0.79
The Skin as an Early Expression of Malignancies in the Neonatal Age: A Review of the Literature and a Case Series. Biomed Res Int (2015) 0.79
Translational development of difluoromethylornithine (DFMO) for the treatment of neuroblastoma. Transl Pediatr (2015) 0.79
Synergy between loss of NF1 and overexpression of MYCN in neuroblastoma is mediated by the GAP-related domain. Elife (2016) 0.78
Immunotherapy in pediatric malignancies: current status and future perspectives. Future Oncol (2014) 0.78
Genetic discoveries and treatment advances in neuroblastoma. Curr Opin Pediatr (2016) 0.77
MYCN controls an alternative RNA splicing program in high-risk metastatic neuroblastoma. Cancer Lett (2015) 0.77
Safety and diagnostic accuracy of tumor biopsies in children with cancer. Cancer (2014) 0.77
Telomere maintenance is pivotal for high-risk neuroblastoma. Cell Cycle (2015) 0.77
The Spectrum and Clinical Impact of Epigenetic Modifier Mutations in Myeloma. Clin Cancer Res (2016) 0.77
In Japanese patients with papillary thyroid carcinoma, TERT promoter mutation is associated with poor prognosis, in contrast to BRAF (V600E) mutation. Virchows Arch (2016) 0.76
Advances in paediatric cancer treatment. Transl Pediatr (2014) 0.76
Aneuploidy in neuroblastoma tumors is not associated with inactivating point mutations in the STAG2 gene. BMC Med Genet (2013) 0.76
More than the genes, the tumor microenvironment in neuroblastoma. Cancer Lett (2015) 0.76
Assessment of the chemosensitizing activity of TAT-RasGAP317-326 in childhood cancers. PLoS One (2015) 0.76
The genetics of splicing in neuroblastoma. Cancer Discov (2015) 0.76
DNA methylation fingerprint of neuroblastoma reveals new biological and clinical insights. Genom Data (2015) 0.76
Tumor Touch Imprints as Source for Whole Genome Analysis of Neuroblastoma Tumors. PLoS One (2016) 0.75
MYCN and HDAC5 transcriptionally repress CD9 to trigger invasion and metastasis in neuroblastoma. Oncotarget (2016) 0.75
Neuroblastoma after childhood: prognostic relevance of segmental chromosome aberrations, ATRX protein status, and immune cell infiltration. Neoplasia (2014) 0.75
Research progress of neuroblastoma related gene variations. Oncotarget (2016) 0.75
Neuroblastoma, a Paradigm for Big Data Science in Pediatric Oncology. Int J Mol Sci (2016) 0.75
Enrichment of Targetable Mutations in the Relapsed Neuroblastoma Genome. PLoS Genet (2016) 0.75
The ATRX cDNA is prone to bacterial IS10 element insertions that alter its structure. Springerplus (2014) 0.75
Pediatric cancer epigenome and the influence of folate. Epigenomics (2015) 0.75
Molecular Classification Substitutes for the Prognostic Variables Stage, Age, and MYCN Status in Neuroblastoma Risk Assessment. Neoplasia (2017) 0.75
Impact of disseminated neuroblastoma cells on the identification of the relapse-seeding clone. Clin Cancer Res (2017) 0.75
Genomic analysis-integrated whole-exome sequencing of neuroblastomas identifies genetic mutations in axon guidance pathway. Oncotarget (2017) 0.75
Telomere measurement by quantitative PCR. Nucleic Acids Res (2002) 18.69
DAXX/ATRX, MEN1, and mTOR pathway genes are frequently altered in pancreatic neuroendocrine tumors. Science (2011) 10.26
The genetic basis of early T-cell precursor acute lymphoblastic leukaemia. Nature (2012) 9.89
Distinct factors control histone variant H3.3 localization at specific genomic regions. Cell (2010) 8.79
Association of multiple copies of the N-myc oncogene with rapid progression of neuroblastomas. N Engl J Med (1985) 7.79
The International Neuroblastoma Risk Group (INRG) classification system: an INRG Task Force report. J Clin Oncol (2008) 6.66
CREST maps somatic structural variation in cancer genomes with base-pair resolution. Nat Methods (2011) 5.34
A novel retinoblastoma therapy from genomic and epigenetic analyses. Nature (2012) 5.02
Targeted expression of MYCN causes neuroblastoma in transgenic mice. EMBO J (1997) 4.99
Daxx is an H3.3-specific histone chaperone and cooperates with ATRX in replication-independent chromatin assembly at telomeres. Proc Natl Acad Sci U S A (2010) 4.73
Altered telomeres in tumors with ATRX and DAXX mutations. Science (2011) 4.60
ATR-X syndrome protein targets tandem repeats and influences allele-specific expression in a size-dependent manner. Cell (2010) 4.34
The death-associated protein DAXX is a novel histone chaperone involved in the replication-independent deposition of H3.3. Genes Dev (2010) 4.00
Neuroblastoma in adults and adolescents: an indolent course with poor survival. Cancer (1997) 1.94
A quantitative real-time PCR method for absolute telomere length. Biotechniques (2008) 1.77
Interval between symptom onset and diagnosis of pediatric solid tumors. J Pediatr (1991) 1.71
Clinical and biologic features predictive of survival after relapse of neuroblastoma: a report from the International Neuroblastoma Risk Group project. J Clin Oncol (2011) 1.62
Alpha thalassaemia-mental retardation, X linked. Orphanet J Rare Dis (2006) 1.51
Outcome of children with neuroblastoma after progression or relapse. A retrospective study of the Italian neuroblastoma registry. Eur J Cancer (2009) 1.44
DNA copy number, including telomeres and mitochondria, assayed using next-generation sequencing. BMC Genomics (2010) 1.41
Neuroblastoma in adolescents and adults: the Memorial Sloan-Kettering experience. Med Pediatr Oncol (2003) 1.40
Clinical prognostic factors in 1277 patients with neuroblastoma: results of The European Neuroblastoma Study Group 'Survey' 1982-1992. Eur J Cancer (2000) 1.32
Changes over three decades in outcome and the prognostic influence of age-at-diagnosis in young patients with neuroblastoma: a report from the International Neuroblastoma Risk Group Project. Eur J Cancer (2010) 1.30
Neuroblastoma in adolescents: the Italian experience. Cancer (2006) 1.19
Advances in the understanding of constitutional and somatic genomic alterations in neuroblastoma. Cancer Genet (2011) 1.06
Chronic neuroblastoma. Cancer (2002) 0.95
Impact of megatherapy on survival after relapse from stage 4 neuroblastoma in patients over 1 year of age at diagnosis: a report from the European Group for Bone Marrow Transplantation. J Clin Oncol (1993) 0.84
Impact of intensified therapy on clinical outcome in infants and children with neuroblastoma: the St Jude Children's Research Hospital experience, 1962 to 1988. J Clin Oncol (1991) 0.84
Studies probe role of telomere length in predicting, modulating cancer risk. JAMA (2011) 0.82
Rapid and accurate determination of MYCN copy number and 1p deletion in neuroblastoma by quantitative PCR. Pediatr Blood Cancer (2006) 0.81
Initial sequencing and comparative analysis of the mouse genome. Nature (2002) 96.15
A second generation human haplotype map of over 3.1 million SNPs. Nature (2007) 85.39
Identification and analysis of functional elements in 1% of the human genome by the ENCODE pilot project. Nature (2007) 75.09
MicroRNA expression profiles classify human cancers. Nature (2005) 69.12
An obesity-associated gut microbiome with increased capacity for energy harvest. Nature (2006) 44.35
Evolutionarily conserved elements in vertebrate, insect, worm, and yeast genomes. Genome Res (2005) 44.08
Integrated genomic analysis identifies clinically relevant subtypes of glioblastoma characterized by abnormalities in PDGFRA, IDH1, EGFR, and NF1. Cancer Cell (2010) 39.09
DNA sequencing of a cytogenetically normal acute myeloid leukaemia genome. Nature (2008) 38.13
Recurring mutations found by sequencing an acute myeloid leukemia genome. N Engl J Med (2009) 33.09
Whole-genome sequencing and variant discovery in C. elegans. Nat Methods (2008) 31.92
Mapping and sequencing of structural variation from eight human genomes. Nature (2008) 30.28
Somatic mutations affect key pathways in lung adenocarcinoma. Nature (2008) 30.02
Genome-wide association study identifies novel breast cancer susceptibility loci. Nature (2007) 29.23
Integrative genomic profiling of human prostate cancer. Cancer Cell (2010) 23.61
Human papillomavirus and survival of patients with oropharyngeal cancer. N Engl J Med (2010) 22.74
Generalized autocalibrating partially parallel acquisitions (GRAPPA). Magn Reson Med (2002) 20.68
International network of cancer genome projects. Nature (2010) 20.35
Genomic and epigenomic landscapes of adult de novo acute myeloid leukemia. N Engl J Med (2013) 19.87
Genome remodelling in a basal-like breast cancer metastasis and xenograft. Nature (2010) 19.68
The B73 maize genome: complexity, diversity, and dynamics. Science (2009) 18.73
BreakDancer: an algorithm for high-resolution mapping of genomic structural variation. Nat Methods (2009) 18.41
Evolution of genes and genomes on the Drosophila phylogeny. Nature (2007) 18.01
Genome-wide analysis of genetic alterations in acute lymphoblastic leukaemia. Nature (2007) 17.68
Genome-wide detection and characterization of positive selection in human populations. Nature (2007) 17.27
Characterizing the cancer genome in lung adenocarcinoma. Nature (2007) 16.48
Evolutionary and biomedical insights from the rhesus macaque genome. Science (2007) 16.21
Identification of a CpG island methylator phenotype that defines a distinct subgroup of glioma. Cancer Cell (2010) 16.12
VarScan: variant detection in massively parallel sequencing of individual and pooled samples. Bioinformatics (2009) 16.04
VarScan 2: somatic mutation and copy number alteration discovery in cancer by exome sequencing. Genome Res (2012) 15.90
Extending assembly of short DNA sequences to handle error. Bioinformatics (2007) 14.46
Clonal evolution in relapsed acute myeloid leukaemia revealed by whole-genome sequencing. Nature (2012) 14.33
Integrated genomic characterization of endometrial carcinoma. Nature (2013) 14.29
DNMT3A mutations in acute myeloid leukemia. N Engl J Med (2010) 14.07
The genome sequence of Caenorhabditis briggsae: a platform for comparative genomics. PLoS Biol (2003) 13.32
Mapping copy number variation by population-scale genome sequencing. Nature (2011) 12.55
The male-specific region of the human Y chromosome is a mosaic of discrete sequence classes. Nature (2003) 12.44
PCAP: a whole-genome assembly program. Genome Res (2003) 12.36
Classification, subtype discovery, and prediction of outcome in pediatric acute lymphoblastic leukemia by gene expression profiling. Cancer Cell (2002) 11.83
Deletion of IKZF1 and prognosis in acute lymphoblastic leukemia. N Engl J Med (2009) 10.54
Cyclic GMP-AMP synthase is a cytosolic DNA sensor that activates the type I interferon pathway. Science (2012) 10.47
Prognostic relevance of integrated genetic profiling in acute myeloid leukemia. N Engl J Med (2012) 10.20
BCR-ABL1 lymphoblastic leukaemia is characterized by the deletion of Ikaros. Nature (2008) 10.12
The genetic basis of early T-cell precursor acute lymphoblastic leukaemia. Nature (2012) 9.89
De novo gene disruptions in children on the autistic spectrum. Neuron (2012) 9.69
The origin and evolution of mutations in acute myeloid leukemia. Cell (2012) 9.66
Genomic analysis of the clonal origins of relapsed acute lymphoblastic leukemia. Science (2008) 9.25
Complete Khoisan and Bantu genomes from southern Africa. Nature (2010) 9.06
A high-resolution map of human evolutionary constraint using 29 mammals. Nature (2011) 8.67
IDH1 mutation is sufficient to establish the glioma hypermethylator phenotype. Nature (2012) 8.66
Comparison of genome degradation in Paratyphi A and Typhi, human-restricted serovars of Salmonella enterica that cause typhoid. Nat Genet (2004) 8.60
Genomic sequence of the pathogenic and allergenic filamentous fungus Aspergillus fumigatus. Nature (2005) 8.55
A catalog of reference genomes from the human microbiome. Science (2010) 8.10